With a price-to-sales (or "P/S") ratio of 0.9x SQZ Biotechnologies Company (NYSE:SQZ) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 11.5x and even P/S higher than 50x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.

Check out our latest analysis for SQZ Biotechnologies

How Has SQZ Biotechnologies Performed Recently?

SQZ Biotechnologies could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.

Want the full picture on analyst estimates for the company? Then our free report on SQZ Biotechnologies will help you uncover what's on the horizon.

Is There Any Revenue Growth Forecasted For SQZ Biotechnologies?

In order to justify its P/S ratio, SQZ Biotechnologies would need to produce anemic growth that's substantially trailing the industry.

Retrospectively, the last year delivered a frustrating 21% decrease to the company's top line. This has soured the latest three-year period, which nevertheless managed to deliver a decent 6.8% overall rise in revenue. Accordingly, while they would have preferred to keep the run going, shareholders would be roughly satisfied with the medium-term rates of revenue growth.

Looking ahead now, revenue is anticipated to climb by 83% per annum during the coming three years according to the three analysts following the company. That's shaping up to be similar to the 92% each year growth forecast for the broader industry.

With this information, we find it odd that SQZ Biotechnologies is trading at a P/S lower than the industry. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.

The Final Word

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've seen that SQZ Biotechnologies currently trades on a lower than expected P/S since its forecast growth is in line with the wider industry. Despite average revenue growth estimates, there could be some unobserved threats keeping the P/S low. However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.